A Canadian Cost Analysis Comparing the Use of Bortezomib or Lenalidomide as Maintenance Therapies in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant
May 1, 2014, 00:00 AM
10.1016/j.jval.2014.03.449
https://www.valueinhealthjournal.com/article/S1098-3015(14)00500-2/fulltext
Section Title :
Cancer
Section Order :
1494
First Page :
A77
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00500-2&doi=10.1016/j.jval.2014.03.449